Use of Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for Mutant Non-Small Cell Lung Cancer.

PURPOSE

Evaluating drug responses using primary patient-derived cells represents a potentially rapid and efficient approach to screening for new treatment approaches. Here, we sought to identify neratinib combinations in mutant non-small cell lung cancer (NSCLC) patient enograft-erived rganotypic pheroids (XDOTS) using a short-term system.

EXPERIMENTAL DESIGN

We generated two mutant NSCLC PDX models [DFCI359 ( exon19 755_757LREdelinsRP) and DFCI315 ( exon20 V777_G778insGSP)] and used the PDX tumors to generate XDOTS. Tumor spheroids were grown in a microfluidic device and treated with neratinib-based drug combinations. Live/dead quantification was performed by dual-labeling deconvolution fluorescence microscopy. The most efficacious combination was subsequently validated using the DFCI359 and DFCI315 PDXs and a genetically engineered mouse model.

RESULTS

Both neratinib and afatinib, but not gefitinib, induced cell death in DFCI359 XDOTS. The combinations of neratinib/trastuzumab and neratinib/temsirolimus enhanced the therapeutic benefit of neratinib alone in DFCI315 and DFCI359. The combination of neratinib and trastuzumab was more effective compared with single-agent neratinib or trastuzumab and was associated with more robust inhibition of HER2 and downstream signaling.

CONCLUSIONS

The XDOTS platform can be used to evaluate therapies and therapeutic combinations using PDX tumors. This approach may accelerate the identification and clinical development of therapies for targets with no or few existing models and/or therapies.